<DOC>
	<DOCNO>NCT01552408</DOCNO>
	<brief_summary>This study Phase I/II , multicenter , randomize , study efficacy safety ranibizumab injection monotherapy verse duel therapy 0.3mg ranibizumab combine ultra wide , 200° field angiography guide pan retinal photocoagulation patient CSME-CI secondary diabetes mellitus ( Type 1 2 ) .</brief_summary>
	<brief_title>Efficacy &amp; Safety Trial Intravitreal Injections Combined With PRP CSME Secondary Diabetes Mellitus ( DAVE )</brief_title>
	<detailed_description>Approximately 40 eye randomize 3 investigational center United States . This study consist screen period 14 day ( Days -14 -1 ) , 36-month treatment period ( Day 0 Month 36 ) . Subjects provide consent enter screen period determine eligibility . As part screen process , examine investigator evaluate macular foveal avascular zone fluorescein image determine subject ' eligibility . Eligible subject randomize 1:1 ratio approximately 20 eye receive 0.3 mg ranibizumab monotherapy , approximately 20 eye receive 0.3 mg ranibizumab combine Ultra wide 200° field angiogram guide target pan retinal photocoagulation ( PRP ) . Subjects must meet VA retinal thickness eligibility requirement screen period . The subject eye study . If eye eligible , one eye randomize , cohort 1 eye randomize cohort 2 . A subject eye trial eye separate cohort .</detailed_description>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Willingness provide sign informed consent Health Insurance Portability Accountability Act ( HIPAA ) authorization . Age ≥ 18 year Diabetes Mellitus ( Type 1 2 ) . The following consider sufficient evidence diabetes present : Current regular use insulin treatment diabetes Current regular use oral antihyperglycemic agent treatment diabetes Documented diabetes accord American Diabetes Association and/or World Health Organization criterion . BCVA score study eye 20/32 20/320 approximate snellen equivalent use ETDRS protocol initial test distance 4 meter , confirm investigator . High Definition OCT ( Spectralis ) central retinal thickness measurement ≥ 300 µm Decrease visual acuity determine primarily result DME cause . Ability willingness return schedule visit assessment . Clear ocular medium adequate pupillary dilatation permit good quality fundus photography . Subjects meet follow criterion exclude study : General Exclusion Criteria Pregnancy ( positive pregnancy test ) lactation Sexually active woman childbearing potential* unwilling practice adequate contraception abstinence study . ( *Although birth control method 100 % effective , follow consider adequate mean contraception : surgical sterilization , use oral contraceptive , barrier contraception use either condom diaphragm spermicidal gel , intrauterine device , contraceptive hormone implant patch . A subject 's primary care physician , obstetrician , gynecologist consult regard appropriate form birth control ) Any condition investigator believe would pose significant hazard subject investigational therapy initiate Participation another simultaneous medical investigation trial ] Ocular Exclusion Criteria Prior Ocular Treatment : History vitrectomy surgery study eye Any panretinal photocoagulation study eye Prior treatment intraocular subconjunctival steroid study eye 4 month prior screen Previous treatment antiangiogenic drug either eye ( pegaptanib sodium , anecortave acetate , bevacizumab , ranibizumab , etc . ) within 2 month Day 0 visit Systemic corticosteroids 4 month prior screen Concurrent Ocular Conditions : Any concurrent ocular condition study eye ( e.g. , cataract agerelated macular degeneration ) , opinion investigator could : require medical surgical intervention study period prevent treat visual loss might result condition ; , allow progress untreated , could likely contribute loss least 2 Snellen equivalent line BCVA study period Active intraocular inflammation ( grade trace ) study eye Current vitreous hemorrhage study eye History rhegmatogenous retinal detachment macular hole ( Stage 3 4 ) study eye Active infectious conjunctivitis , keratitis , scleritis , endophthalmitis either eye Aphakia absence posterior capsule study eye Intraocular surgery ( include cataract surgery ) study eye within 2 month precede Day 0 Uncontrolled glaucoma study eye ( defined IOP ≥ 30 mmHg despite treatment antiglaucoma medication ) History glaucomafiltering surgery study eye History corneal transplant study eye High Risk PDR : New vessel within one disc diameter optic nerve head large onethird disc area Vitreous preretinal hemorrhage associate less extensive NVD NVE onehalf disc area size Extensive damage fovea vascular zone determine principal investigator designate site personnel Spherical equivalent refractive error study eye 8.00 diopter myopia Vitreomacular traction ( vitreomacular attachment ok ) Concurrent Systemic Conditions Uncontrolled blood pressure ( define systolic &gt; 180 mmHg and/or diastolic &gt; 110 mmHg patient seat . *If subject 's initial reading exceeds value , second reading may take 30 minute later . If subject 's blood pressure need control antihypertensive medication , subject become eligible medication take continuously least 30 day prior Day 0 Atrial fibrillation manage subject 's primary care physician cardiologist within 3 month screen visit History stroke within last 3 month screen visit History disease , metabolic dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use investigational drug might affect interpretation result study render patient high risk treatment complication Current treatment active systemic infection Active malignancy History allergy fluorescein , amenable treatment Inability obtain fundus photograph fluorescein angiograms sufficient quality analyze grade . Previous participation study investigational drug within 1 month precede Day 0 ( exclude vitamin mineral )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Non Proliferative Diabetic Retinopathy</keyword>
	<keyword>Diabetic Retinopathy</keyword>
	<keyword>Macular Edema</keyword>
	<keyword>Background Diabetic Retinopathy</keyword>
	<keyword>Pre Proliferative Diabetic Retinopathy</keyword>
</DOC>